Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Select Medical Holdings / Equity Bottom-Up

<ul>
 <li>Select Medical is a leading operator in the post-acute care sector, with a diversified model across critical illness recovery hospitals, inpatient rehabilitation, and outpatient clinics. Its scale and joint venture strategy with large health systems provide a competitive advantage.</li>
 <li>The company faces significant headwinds from reimbursement pressure, particularly from Medicare and Medicare Advantage plans, which constitutes a substantial portion of its revenue. Labor shortages and wage inflation also pose a persistent challenge to profitability.</li>
 <li>Demographic tailwinds, specifically the aging U.S. population, provide a long-term driver for demand across all of the company's service lines. However, the company's recent financial performance has been mixed, with declining margins and a significant dividend reduction in 2025.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Select Medical is a leading operator in the post-acute care sector, with a diversified model across critical illness recovery hospitals, inpatient rehabilitation, and outpatient clinics. Its scale and joint venture strategy with large health systems provide a competitive advantage.
  The company faces significant headwinds from reimbursement pressure, particularly from Medicare and Medicare Advantage plans, which constitutes a substantial portion of its revenue. Labor shortages and wage inflation also pose a persistent challenge to profitability.
  Demographic tailwinds, specifically the aging U.S. population, provide a long-term driver for demand across all of the company's service lines. However, the company's recent financial performance has been mixed, with declining margins and a significant dividend reduction in 2025.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Select Medical Holdings (SEM US) - Aug 2026

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Healthcare providers rarely dominate Wall Street headlines.</li><li>Yet Select Medical’s recent buyout agreement has suddenly pushed the sector into the spotlight.</li><li>The rehabilitation and post-acute care operator announced that a consortium led by Executive Chairman Robert Ortenzio, senior executive Martin Jackson, and private equity firm Welsh, Carson, Anderson & Stowe will acquire the company in a deal valued at roughly $3.9 billion, offering shareholders $16.50 per share in cash.</li></ul>

Healthcare providers rarely dominate Wall Street headlines.Yet Select Medical’s recent buyout agreement has suddenly pushed the sector into the spotlight.The rehabilitation and post-acute care operator announced that a consortium led by Executive Chairman Robert Ortenzio, senior executive Martin Jackson, and private equity firm Welsh, Carson, Anderson & Stowe will acquire the company in a deal valued at roughly $3.9 billion, offering shareholders $16.50 per share in cash.

Select Medical Goes Private—Is This the Start of a Healthcare Exodus?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>The S&amp;P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks.</li>
<li>Using the 2007 SPX topping analog suggests a 2% or less move above the prior all-time high set in July at 5670 before topping, which gives the 5783 number.</li>
<li>As long as SPX does not have a weekly close above 5783 we continue to recommend reducing risk and shifting to defensives,and this is the ideal time to do so.</li>
</ul>


The S&amp;P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks.
Using the 2007 SPX topping analog suggests a 2% or less move above the prior all-time high set in July at 5670 before topping, which gives the 5783 number.
As long as SPX does not have a weekly close above 5783 we continue to recommend reducing risk and shifting to defensives,and this is the ideal time to do so.


SPX Testing Resistance as Rate Cut Cycle Begins; SPX 5670-5783 Is Resistance, 2007 Analog on Track

<ul>
<li>Breadth continues to improve and Russell 2000 (IWM) small-caps and the Dow remain bullish, all while the S&amp;P 500 and Nasdaq 100 (QQQ) are going through a pullback/consolidation phase.</li>
<li>Considering the Russell 2000 vs. S&amp;P 500 ratio is reversing a 3.5-year downtrend, we expect this trend of small-cap outperformance to continue for months or longer.</li>
<li>With new risk-off signals emerging, potential pullback zones we would look for include 5100-5191 on the S&amp;P 500 and $443-$449 on the QQQ, expecting a low near the election.</li>
</ul>


Breadth continues to improve and Russell 2000 (IWM) small-caps and the Dow remain bullish, all while the S&amp;P 500 and Nasdaq 100 (QQQ) are going through a pullback/consolidation phase.
Considering the Russell 2000 vs. S&amp;P 500 ratio is reversing a 3.5-year downtrend, we expect this trend of small-cap outperformance to continue for months or longer.
With new risk-off signals emerging, potential pullback zones we would look for include 5100-5191 on the S&amp;P 500 and $443-$449 on the QQQ, expecting a low near the election.


Upgrading Health Care to Market Weight; Risk-Off Signals Suggest SPX and QQQ Pullback to Continue

Today we highlight several metrics which provide evidence that risk appetites are improving, not deteriorating. This is a bullish signal for the broad market. Still, we continue to see a mixed market environment, but we remain constructive overall with the S&amp;P 500 holding above short-term support at the 50-day moving average and 4056.

Today we highlight several metrics which provide evidence that risk appetites are improving, not deteriorating. This is a bullish signal for the broad market. Still, we continue to see a mixed market environment, but we remain constructive overall with the S&amp;P 500 holding above short-term support at the 50-day moving average and 4056.

Risk Appetites Improving, A Bullish Sign; Downgrading Technology To Underweight

United States

Select Medical Holdings Corporation is an operator of specialty hospitals and outpatient rehabilitation clinics. The Company provides medical rehabilitation services on a contract basis at nursing homes, hospitals, assisted living and senior care centers, schools and work sites.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Select Medical Holdings (SEM US)

Primer: Select Medical Holdings (SEM US) - Aug 2026

Select Medical is a leading operator in the post-acute care sector, with a diversified model across critical illness recovery hospitals,...

αSK Primers

Select Medical Goes Private—Is This the Start of a Healthcare Exodus?

Healthcare providers rarely dominate Wall Street headlines. Yet Select Medical’s recent buyout agreement has suddenly pushed the sector into the...

Baptista Research

SPX Testing Resistance as Rate Cut Cycle Begins; SPX 5670-5783 Is Resistance, 2007 Analog on Track

$SPX Testing Resistance as Rate Cut Cycle Begins; SPX 5670-5783 is Resistance, 2007 Analog on Track if Below 5783. Still Neutral, prefer to sell...

Vermilion Research

Upgrading Health Care to Market Weight; Risk-Off Signals Suggest SPX and QQQ Pullback to Continue

Upgrading Health Care $XLV to Market Weight; New Risk-Off Signals Suggest Pullback in $SPX and $QQQ to Continue, looking for pullbacks to 5100-5191...

Vermilion Research

Risk Appetites Improving, A Bullish Sign; Downgrading Technology To Underweight

Below we highlight several metrics which provide evidence that risk appetites are improving, not deteriorating. This is a bullish signal for the...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)